FDA Considers Three-Parent IVF

The US regulatory agency will meet next week to discuss whether to allow human trials of a technique that combines the genetic information of three adults.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, EKEMTo prevent the passage of mitochondrial disorders from mother to child, researchers have devised a clever solution: take the nucleus of a woman carrying harmful mutations in her mitochondrial DNA and transfer it to an enucleated egg of another woman without such defects. The hybrid egg, which carries the nuclear DNA of the mother-to-be and healthy mitochondria from the egg donor, can then be fertilized in vitro with sperm from the would-be father, and the resulting embryos implanted into mom.

The technique has proven successful in human cells in the lab, and has even resulted in the generation of seemingly healthy rhesus monkeys. But such three-way parenthood in vitro fertilization (IVF) is not without controversy, with many concerned scientists and citizens raising legal, ethical, and logistical issues. Next week (October 22), the US Food and Drug Administration (FDA) will meet in Silver Spring, Maryland, to discuss these issues, and decide whether to permit the launch of clinical trials to test the technique.

High on the FDA’s list of items to discuss is undoubtedly the safety concerns that have been raised. When developing three-parent embryos in the lab, developmental biologist Shoukhrat Mitalipov at Oregon Health & Science University in Beaverton detected genetic abnormalities in about half ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo